In earnings' conference call, Jhunjhunwala who currently holds 1.12 percent stake in the company threw a volley of questions to the management. The big bull raised questions on Aurobindo Pharma's finance cost, capex, rationale behind investment in vaccines, product launch, potential revenue growth and its fund raising plans.
first published: Aug 24, 2016 02:33 pm
A collection of the most-viewed Moneycontrol videos.
Live: Nifty sees best single day rally since June 2025, nears record high | Closing Bell
Live: Can Nifty claim new lifetime highs in December series? | Opening Bell
Live: Sensex, Nifty rangebound on monthly expiry day | Closing Bell
Live: Will Nifty's downtrend continue to third session on expiry day? | Opening Bell
